Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Halozyme Therapeutic (HALO)

Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,031,668
  • Shares Outstanding, K 123,221
  • Annual Sales, $ 1,015 M
  • Annual Income, $ 444,090 K
  • EBIT $ 669 M
  • EBITDA $ 746 M
  • 60-Month Beta 1.26
  • Price/Sales 5.81
  • Price/Cash Flow 10.80
  • Price/Book 12.87

Options Overview Details

View History
  • Implied Volatility 46.32% ( -3.02%)
  • Historical Volatility 102.25%
  • IV Percentile 93%
  • IV Rank 67.34%
  • IV High 59.09% on 04/04/25
  • IV Low 19.97% on 06/04/24
  • Put/Call Vol Ratio 1.17
  • Today's Volume 2,025
  • Volume Avg (30-Day) 1,280
  • Put/Call OI Ratio 0.36
  • Today's Open Interest 21,706
  • Open Int (30-Day) 11,496

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate 1.13
  • Number of Estimates 5
  • High Estimate 1.23
  • Low Estimate 1.02
  • Prior Year 0.85
  • Growth Rate Est. (year over year) +32.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
47.50 +3.05%
on 05/14/25
70.50 -30.57%
on 05/07/25
-12.33 (-20.12%)
since 04/15/25
3-Month
47.50 +3.05%
on 05/14/25
70.50 -30.57%
on 05/07/25
-9.34 (-16.02%)
since 02/14/25
52-Week
42.01 +16.52%
on 11/18/24
70.50 -30.57%
on 05/07/25
+3.13 (+6.83%)
since 05/15/24

Most Recent Stories

More News
Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus

Kodiak Sciences KOD incurred a loss of $1.09 per share in the first quarter of 2025, wider than the Zacks Consensus Estimate of a loss of 89 cents. The company had incurred a loss of 82 cents per share...

ALLO : 1.0900 (+14.40%)
KOD : 3.33 (-15.48%)
HALO : 48.95 (+2.17%)
Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus

Fate Therapeutics FATE reported a loss of 32 cents per share for the first quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of 39 cents. The company had reported a loss of 47 cents...

ALLO : 1.0900 (+14.40%)
FATE : 1.0100 (+5.21%)
HALO : 48.95 (+2.17%)
Halozyme Therapeutics: Q1 Earnings Snapshot

Halozyme Therapeutics: Q1 Earnings Snapshot

HALO : 48.95 (+2.17%)
Halozyme Therapeutics: Q4 Earnings Snapshot

Halozyme Therapeutics: Q4 Earnings Snapshot

HALO : 48.95 (+2.17%)
Blueprint Stock Soars 18% on Encouraging 2025 Growth Strategy

Shares of Blueprint Medicines BPMC rallied 18.2% on Monday driven by investor enthusiasm following the company’s announcement of its 2025 corporate outlook and growth strategy, highlighting plans to...

CTMX : 2.00 (-15.97%)
CSTL : 16.48 (+0.98%)
BPMC : 99.49 (+2.03%)
HALO : 48.95 (+2.17%)
PCRX Stock Rises 11% on Upbeat Q4 Preliminary Product Sales

Shares of Pacira BioSciences PCRX gained 11.1% on Friday after the company shared better-than-expected preliminary fourth-quarter 2024 sales figures for its marketed products.Additionally, the company...

CTMX : 2.00 (-15.97%)
CSTL : 16.48 (+0.98%)
PCRX : 25.60 (+4.70%)
HALO : 48.95 (+2.17%)
SANA Stock Surges 152% in a Week on Upbeat Initial Diabetes Study Data

Shares of Sana Biotechnology SANA skyrocketed 151.5% in the past week after the company announced positive initial results from a potentially groundbreaking type 1 diabetes (T1D) study of its experimental...

CTMX : 2.00 (-15.97%)
CSTL : 16.48 (+0.98%)
SANA : 1.7100 (-3.93%)
HALO : 48.95 (+2.17%)
Are Options Traders Betting on a Big Move in Halozyme (HALO) Stock?

Investors in Halozyme Therapeutics, Inc. HALO need to pay close attention to the stock based on moves in the options market lately. That is because the March 21, 2025 $25.00 Call had some of the highest...

HALO : 48.95 (+2.17%)
FDA Clears PCRX's New Iovera Smart Tip for Expanded Use in Pain Relief

Pacira BioSciences PCRX announced that the FDA has cleared its application to market a new Smart Tip for the iovera system designed to access the medial branch nerves to manage chronic low back pain....

CTMX : 2.00 (-15.97%)
CSTL : 16.48 (+0.98%)
PCRX : 25.60 (+4.70%)
HALO : 48.95 (+2.17%)
Geron Stock Rallies More Than 60% in a Year: Here's Why

For Geron Corporation GERN, 2024 was a transformational year as it saw the FDA approval and commercial launch of Rytelo (imetelstat) for the treatment of low- to intermediate-1 risk myelodysplastic syndromes...

PBYI : 3.28 (+13.10%)
CSTL : 16.48 (+0.98%)
GERN : 1.2100 (+1.68%)
HALO : 48.95 (+2.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Halozyme Therapeutics Inc. is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company's ENHANZE drug delivery technology helps in developing subcutaneous formulation of drugs. The company...

See More

Key Turning Points

3rd Resistance Point 51.81
2nd Resistance Point 50.76
1st Resistance Point 49.85
Last Price 48.95
1st Support Level 47.89
2nd Support Level 46.84
3rd Support Level 45.93

See More

52-Week High 70.50
Fibonacci 61.8% 59.62
Fibonacci 50% 56.26
Fibonacci 38.2% 52.90
Last Price 48.95
52-Week Low 42.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar